Accelerating drug development by efficiently using emerging PK/PD data from an adaptable entry-into-human trial: example of lumretuzumab
Crossref DOI link: https://doi.org/10.1007/s00280-017-3328-3
Published Online: 2017-05-11
Published Print: 2017-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Meneses-Lorente, Georgina
McIntyre, Christine
Hsu, Joy C.
Thomas, Marlene
Jacob, Wolfgang
Adessi, Celine
Weisser, Martin
Funding for this research was provided by:
Roche Diagnostics GmBH, Penzberg, Germany
License valid from 2017-05-11